À̺¥Æ® ¼Ò°³
2025³â PEGS Boston SummitÀº ¹ÙÀÌ¿À·ÎÁ÷½º¡¤´Ü¹éÁú ¿£Áö´Ï¾î¸µÀÇ ÁÖ·Â À̺¥Æ®·Î¼ÀÇ ÁöÀ§¸¦ À¯ÁöÇÏ¸é¼ °ú°ÅÀÇ ¼º°øÀ» ¶Ù¾î³Ñ°í ÀÖ½À´Ï´Ù. Àü¹®°¡, À̳뺣ÀÌÅÍ, ±Û·Î¹ú ¸®´õ°¡ ÇÑÀÚ¸®¿¡ ¸ð¿© ÀǰßÀ» ±³È¯Çϰí, ±³·ùÇÏ´Â Àå¼ÒÀÔ´Ï´Ù!
¾÷°è¿¡¼ °¡Àå ¿µÇâ·Â ÀÖ°í, »ý°¢À» ÀÚ±ØÇÏ´Â ¿¬»çÀÇ À̾߱⸦ µéÀ» ¼ö ÀÖ½À´Ï´Ù.
- ÁÖ¿ä ¿¬±¸ÀÚ ¹× »ç°í ¸®´õ 350¸íÀÌ Çõ½ÅÀûÀÎ ÇÁ·¹Á¨Å×ÀÌ¼Ç ¹× »ç·Ê ¿¬±¸¸¦ °øÀ¯Çϰí, ÆÐ³Î µð½ºÄ¿¼ÇÀ» ÁÖµµÇϰí, ÀÎÅÍ·¢Æ¼ºê ºê·¹ÀÌÅ©¾Æ¿ô µð½ºÄ¿¼ÇÀ» ÁøÇàÇÕ´Ï´Ù.
- ÁÖ¿ä Å×Å©³î·¯Áö ÇÁ·Î¹ÙÀÌ´õ ¹× ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡ ÀÇÇÑ ½ºÆù¼ Á¦°ø °¿¬¿¡¼´Â ÃÖ÷´Ü Å×Å©³î·¯Áö ¹× ½Å»óǰ µîÀÌ ¼Ò°³µË´Ï´Ù.
»õ·Î¿î Àü·«, ÃֽŠÇõ½Å Å×Å©³î·¯Áö, º£½ºÆ® ÇÁ·¢Æ¼½º¿¡ °üÇÑ ÀλçÀÌÆ®¸¦ ¾ò°í, ÀÚ½ÅÀÇ ¿¬±¸¸¦ ´ÙÀ½ ·¹º§·Î ÁøÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ´Ü¹éÁú¡¤Ç×ü °øÇÐ, ÀÌÁ߯¯À̼ºÇ×ü °³¹ß, ¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ Æ¯¼º Æò°¡, ´Ü¹éÁú ¹ßÇö Ç÷§Æû, AI/ML µå¸®ºì ¹ÙÀÌ¿À·ÎÁ÷½º ¿¬±¸ µî 20°³ÀÇ ÄÁÆÛ·±½º ÇÁ·Î±×·¥°ú Æ®·¹ÀÌ´× ¼¼¹Ì³ª¿¡¼ »ó¼¼ÇÏ°Ô ¼³¸íÇÕ´Ï´Ù.
- ÀÎÅÍ·¢Æ¼ºê ºê·¹ÀÌÅ©¾Æ¿ô ¼¼¼Ç¿¡¼´Â ÃËÁøµÈ ¼Ò±×·ì µð½ºÄ¿¼ÇÀ» ÁøÇàÇÕ´Ï´Ù.
- µî·Ï ¿É¼Ç¿¡ ÀÇÇØ ¿©·¯ºÐÀÇ ½ºÄÉÁÙ ¹× ¿¬±¸ ¸ñÇ¥¿¡ ¸ÂÃß¾î ±³À° ¹× ³×Æ®¿öÅ· ¾ÆÁ¨´Ù¸¦ Ä¿½ºÅ͸¶ÀÌÁîÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ »ç°í ¸®´õ¿Í ¿¬°áµÇ°í, µ¿·á¿Í Çù¾÷Çϰí, ³×Æ®¿öÅ©¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ¹ÙÀÌ¿ÀÀǾàǰÀÇ Áøº¸¿¡¼ÀÇ °úÁ¦¿Í ±âȸ¿¡ ÃÊÁ¡À» ¸ÂÃß°í, Àü ¼¼°èÀÇ ¿¬±¸ÀÚ¿Í ±³·ùÇÒ ¼ö ÀÖ½À´Ï´Ù.
- µµÂøÇϱâ ÀüºÎÅÍ ´ëȸ¦ ½ÃÀÛÇսôÙ! µðÁöÅÐ Ç÷§Æû¿¡ ÀÇÇØ °°Àº Èï¹Ì³ª ¸ñÇ¥¸¦ °¡Áø Âü°¡ÀÚ¿Í ¿¬°áµÉ ¼ö ÀÖ½À´Ï´Ù.
- Ä¿¹Â´ÏƼ¿¡ Âü°¡ÇսôÙ! LinkedIn ¹× X¿¡¼ #PEGSummitÀ» ÆÈ·Î¿ìÇϼ¼¿ä.
- µ¿½Ã °³ÃÖ ÄÁÆÛ·±½º ÇÁ·Î±×·¥ °£ 'Æ®·¢ È£ÇÎ'¿¡ ÀÇÇØ ¿©·¯ºÐÀÇ °æÇèÀ» Ä¿½ºÅ͸¶ÀÌÁîÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÇØ´ç ÄÁÆÛ·±½º´Â Á¾·áµÇ¾ú½À´Ï´Ù.
2025³â ÇÁ·Î±×·¥
Ç¥½ÃÇϱâ:

°øÇÐ ½ºÆ®¸²
- Display of Biologics
¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ µð½ºÇ÷¹ÀÌ - Engineering Antibodies
Ç×ü °øÇÐ - Machine Learning for Protein Engineering
´Ü¹éÁú ¿£Áö´Ï¾î¸µ¿ë ±â°èÇнÀ

Á¾¾ç ½ºÆ®¸²
- Antibodies for Cancer Therapy
¾ÏÄ¡·á¿ë Ç×ü - Emerging Targets for Oncology & Beyond
Á¾¾ç ÀÌ¿Ü ½Å±Ô Ÿ±ê - Driving Clinical Success in Antibody-Drug Conjugates
Ç×ü¾à¹°Á¢ÇÕü(ADC)ÀÇ ÀÓ»óÀû ¼º°øÀÇ ÃßÁø

´ÙÁ߯¯À̼º ½ºÆ®¸²
- TS: Intro to Multispecific Antibodies
Æ®·¹ÀÌ´× ¼¼¹Ì³ª : ´ÙÁ߯¯À̼ºÇ×ü ÀÔ¹® - Advancing Multispecific Antibodies
´ÙÁ߯¯À̼ºÇ×üÀÇ Áøº¸ - Engineering Bispecific and Multifunctional Antibodies
ÀÌÁ߯¯À̼ºÇ×ü¡¤´Ù±â´É Ç×ü °øÇÐ

¸é¿ªÄ¡·á ½ºÆ®¸²
- Advances in Immunotherapy
¸é¿ªÄ¡·áÀÇ Áøº¸ - Engineering Cell Therapies
¼¼Æ÷Ä¡·á °øÇÐ - Next-Generation Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á

¹ßÇö ½ºÆ®¸²
- Difficult-to-Express Proteins
¹ßÇöÀÌ ¾î·Á¿î ´Ü¹éÁú - Optimizing Protein Expression
´Ü¹éÁú ¹ßÇöÀÇ ÃÖÀûÈ - Maximizing Protein Production Workflows
´Ü¹éÁú »ý»ê ¿öÅ©Ç÷οìÀÇ ÃÖ´ëÈ

ºÐ¼®¹ý ½ºÆ®¸²
- ML and Digital Integration in Biotherapeutic Analytics
¹ÙÀÌ¿ÀÀǾàǰ ºÐ¼®¿¡¼ ML°ú µðÁöÅÐ ÅëÇÕ - Biophysical Methods
»ý¹°¹°¸®ÇÐÀû ¹æ¹ý - Characterization for Novel Biotherapeutics
½Å±Ô ¹ÙÀÌ¿ÀÀǾàǰÀÇ Æ¯¼º Æò°¡

¸é¿ª¿ø¼º ½ºÆ®¸²
- TS: Intro to Immunogenicity
Æ®·¹ÀÌ´× ¼¼¹Ì³ª : ¸é¿ª¿ø¼º ÀÔ¹® - Predicting Immunogenicity with AI/ML Tools
AI/ML Åø¿¡ ÀÇÇÑ ¸é¿ª¿ø¼º ¿¹Ãø - TS: Bioassay Development and Analysis
Æ®·¹ÀÌ´× ¼¼¹Ì³ª : ¹ÙÀÌ¿À¾î¼¼ÀÌ °³¹ß°ú ºÐ¼®

½Å±Ô Ä¡·á ½ºÆ®¸²
- Biologics for Immunology Indications
ÀûÀÀ ¸é¿ª¿ë ¹ÙÀÌ¿À·ÎÁ÷½º - Radiopharmaceutical Therapies
¹æ»ç¼º ÀǾàǰ Ä¡·á - Next-Generation Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á

±â°èÇнÀ ½ºÆ®¸²
- ML and Digital Integration in Biotherapeutic Analytics
¹ÙÀÌ¿ÀÀǾàǰ ºÐ¼®¿¡¼ ML°ú µðÁöÅÐ ÅëÇÕ - Predicting Immunogenicity with AI/ML Tools
AI/ML Åø¿¡ ÀÇÇÑ ¸é¿ª¿ø¼º ¿¹Ãø - Machine Learning for Protein Engineering
´Ü¹éÁú ¿£Áö´Ï¾î¸µ¿ë ±â°èÇнÀ